Legal status | |
---|---|
Legal status |
|
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C10H11ClF3N3 |
Molar mass | 265.662 g/mol |
3D model (Jmol) | |
|
|
|
|
(what is this?) |
Org 12962 is a drug developed by Organon, which acts as a potent and selective agonist for the 5-HT2 receptor family, with highest affinity at 5-HT2C and lowest at 5-HT2B subtypes. It was developed as a potential anti-anxiety drug, but was discontinued from human trials after tests in a public speaking challenge showed that its anti-anxiety effects were accompanied by side effects such as dizziness and a "spacey" feeling, which were attributed to poor selectivity in vivo over the hallucinogenic 5-HT2A receptor.